Biomunex Pharmaceuticals

Biomunex Pharmaceuticals company information, Employees & Contact Information

Updated June 2026

Quick answer

Biomunex Pharmaceuticals is a Biotechnology Research company. It has approximately 12 employees on record. Contact data was last refreshed in June 2026. Find Biomunex Pharmaceuticals's verified employee emails, phone numbers, headquarters address, and key decision makers below.

BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies. Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

Company Details

Employees
12
Address
113 Rue De La Tour, Paris,75116,france
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
PARIS
Looking for a particular Biomunex Pharmaceuticals employee's phone or email?

Biomunex Pharmaceuticals Questions

News

New investors for Biomunex Pharmaceuticals - The Pharma Letter

New investors for Biomunex Pharmaceuticals The Pharma Letter

Ipsen and Biomunex announce exclusive global licensing - GlobeNewswire

Ipsen and Biomunex announce exclusive global licensing GlobeNewswire

Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager - PMLiVE

Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager PMLiVE

Ipsen finds a MAIT in Biomunex | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Ipsen finds a MAIT in Biomunex | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Ipsen and Biomunex enter agreement for BMX-502 - Pharmaceutical Technology

Ipsen and Biomunex enter agreement for BMX-502 Pharmaceutical Technology

Ipsen enlists MAITs to take down solid tumors, betting $610M on Biomunex's novel T-cell engagers - Fierce Biotech

Ipsen enlists MAITs to take down solid tumors, betting $610M on Biomunex's novel T-cell engagers Fierce Biotech

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology - PR Newswire

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology PR Newswire

Ipsen bets $600M on Biomunex’s preclinical T-cell engager - FirstWord Pharma

Ipsen bets $600M on Biomunex’s preclinical T-cell engager FirstWord Pharma

French Ipsen inks US$610m biobucks deal with Biomunex SA - European Biotechnology Magazine

French Ipsen inks US$610m biobucks deal with Biomunex SA European Biotechnology Magazine

Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer - Institut Curie - Espace presse

Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer Institut Curie - Espace presse

Top Biomunex Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant